Rani Therapeutics Holdings Inc Dossier
Qualitative Analysis
Business overview
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) is a clinical-stage biotherapeutics company focused on the oral delivery of biologics and large-molecule drugs. The company's core innovation is the RaniPill® capsule, a proprietary, patented platform technology designed to replace subcutaneous injections or intravenous infusions with oral dosing. The RaniPill® capsule is designed to navigate the gastrointestinal tract and deliver a pain-free micro-injection directly into the intestinal wall, where there are no sharp pain receptors, achieving bioavailability comparable to traditional injections. Rani's pipeline includes clinical and preclinical candidates targeting high-value therapeutic areas such as osteoporosis (RT-102), obesity (RT-114), and various inflammatory conditions (RT-111).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Developing and optimizing the RaniPill capsule, a novel, proprietary, and patented platform technology designed to replace subcutaneous injections or intravenous infusions of biologics with oral dosing.
Expected impact: Aims to disrupt the treatment paradigm for chronic diseases by offering a convenient oral alternative to painful injections.
Advancing RT-114, an oral GLP-1/GLP-2 dual agonist (PG-102) delivered via the RaniPill capsule, into clinical development.
Expected impact: Establishes a competitive footprint in the rapidly expanding global obesity market, which is projected to exceed $100 billion by 2030.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Validates Rani's proprietary RaniPill platform technology and provides substantial non-dilutive funding to support pipeline progression.
Terms: Potential total value of up to approximately $1.085 billion. Includes a $10 million upfront payment, up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones, and single-digit royalties on product sales for the first license agreement, with options for Chugai to expand to 5 additional targets.
Enables the development of RT-114, combining ProGen's bispecific GLP-1/GLP-2 receptor agonist (PG-102) with Rani's oral delivery capsule.
Terms: Joint development and commercialization terms for the RT-114 obesity program.